| Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia M Morari, A Brugnoli, CA Pisanò, S Novello, C Caccia, E Melloni, ... Journal of Pharmacology and Experimental Therapeutics 364 (2), 198-206, 2018 | 49 | 2018 |
| Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease CA Pisanò, A Brugnoli, S Novello, C Caccia, C Keywood, E Melloni, ... Neuropharmacology 167, 108006, 2020 | 33 | 2020 |
| Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia F Gardoni, M Morari, J Kulisevsky, A Brugnoli, S Novello, CA Pisano, ... Journal of Pharmacology and Experimental Therapeutics 367 (3), 442-451, 2018 | 28 | 2018 |
| Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists L Arcuri, S Novello, M Frassineti, D Mercatelli, CA Pisanò, I Morella, ... British journal of pharmacology 175 (5), 782-796, 2018 | 22 | 2018 |
| Leucine‐rich repeat kinase 2 (LRRK 2) inhibitors differentially modulate glutamate release and Serine935 LRRK 2 phosphorylation in striatal and cerebrocortical synaptosomes D Mercatelli, P Bolognesi, M Frassineti, CA Pisanò, F Longo, ... Pharmacology research & perspectives 7 (3), e00484, 2019 | 16 | 2019 |
| 6‐Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata S Vegas‐Suárez, CA Pisanò, C Requejo, H Bengoetxea, JV Lafuente, ... British Journal of Pharmacology 177 (17), 3957-3974, 2020 | 13 | 2020 |
| Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats A Brugnoli, CA Pisanò, M Morari Neurobiology of disease 144, 105044, 2020 | 12 | 2020 |
| Discovery and Structure–Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models UG Kamakolanu, ME Meyer, D Yasuda, WE Polgar, M Marti, D Mercatelli, ... Journal of Medicinal Chemistry 63 (5), 2688-2704, 2020 | 11 | 2020 |
| NOP receptor ligands and Parkinson’s disease D Mercatelli, CA Pisanò, S Novello, M Morari The Nociceptin/Orphanin FQ Peptide Receptor, 213-232, 2019 | 11 | 2019 |
| A mouse model of sleep disorders in Parkinson’s disease showing distinct effects of dopamine D2-like receptor activation D de Castro Medeiros, C Plewnia, RV Mendes, CA Pisanò, L Boi, ... Progress in Neurobiology 231, 102536, 2023 | 2 | 2023 |
| RGS4 negatively modulates Nociceptin/Orphanin FQ opioid receptor signaling: implication for L-Dopa induced dyskinesia CA Pisanò, D Mercatelli, M Mazzocchi, A Brugnoli, I Morella, S Fasano, ... Authorea Preprints, 2021 | 1 | 2021 |
| Therapeutic potential of RGS4 blockade in movement disorders CA Pisanò Università degli studi di Ferrara, 2020 | | 2020 |
| Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats CA Pisano, A Brugnoli, S Novello, C Caccia, C Keywood, E Melloni, ... MOVEMENT DISORDERS 34, S144-S144, 2019 | | 2019 |
| Safinamide inhibition of in vivo glutamate release in a rat model of Parkinson's Disease G Padoani, S Novello, C Pisano, C Caccia, E Melloni, S Vailati, ... MOVEMENT DISORDERS 33, S81-S82, 2018 | | 2018 |
